CUSP 03
Alternative Names: CUSP-03Latest Information Update: 12 Jul 2022
At a glance
- Originator Unknown
- Developer OnCusp Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 20 Jun 2022 Early research in Haematological malignancies in USA as of June 2022 (unspecified route) (OnCusp Therapeutics website, June 2022)
- 20 Jun 2022 Early research in Solid tumours in USA, as of June 2022 (unspecified route) (OnCusp Therapeutics website, June 2022)